Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MicroRNA expression in lymphoma.

Charles H Lawrie1

  • 1University of Oxford, Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, OX3 9DU, UK. charles.lawrie@ndcls.ox.ac.uk

Expert Opinion on Biological Therapy
|August 31, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction notice to "Targeting oncogenic functions of miR-301a in head and neck squamous cell carcinoma by PI3K/PTEN and MEK/ERK pathways" [Biomedicine & Pharmacotherapy 161 (2023) 114512].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Longitudinal Monitoring of Metabolic Gradients in Microreactor Culture Platforms by Raman Spectroscopy.

Biosensors·2026
Same author

MicroRNA Expression During Long-Term Treatment With 3-MCPD and Glycidol In Vitro.

Journal of applied toxicology : JAT·2025
Same author

Fibroblast Activation Protein Alpha (FAP) Expression Is Associated with Disease Recurrence and Poor Response to Tyrosine Kinase Inhibitors in Advanced Clear Cell Renal Cell Carcinoma.

International journal of molecular sciences·2025
Same author

Organoid-on-a-chip (OrgOC): Advancing cystic fibrosis research.

Materials today. Bio·2025
Same author

Solving Mazes of Organelle-Targeted Therapies with DNA Nanomachines.

Advanced materials (Deerfield Beach, Fla.)·2025
Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026
Same journal

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026
Same journal

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Expert opinion on biological therapy·2026
Same journal

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026
Same journal

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026
Same journal

Optimizing biologic therapy in psoriasis: dose adjustment, treatment duration, and tapering-an expert perspective.

Expert opinion on biological therapy·2026
See all related articles

MicroRNAs regulate gene expression and are crucial in blood cell development and blood cancers. Aberrant microRNA expression is implicated in various cancers, including lymphoma.

Area of Science:

  • Molecular Biology
  • Genetics
  • Oncology

Background:

  • MicroRNAs (miRNAs) are short, non-coding RNA molecules regulating gene expression post-transcriptionally.
  • miRNAs are implicated in diverse biological processes and are frequently dysregulated in cancers.
  • Aberrant miRNA expression is observed in various hematological malignancies, acting as tumor suppressors or oncogenes.

Purpose of the Study:

  • To review the accumulating evidence on the role of miRNAs in hematopoiesis.
  • To discuss the significance of miRNAs in hematological malignancies, with a focus on lymphoma.

Main Methods:

  • Literature review of studies investigating miRNA function in hematopoiesis and hematological malignancies.
  • Focus on evidence related to miRNA involvement in lymphoma development and progression.

Related Experiment Videos

Main Results:

  • miRNAs play a central role in normal blood cell development (hematopoiesis).
  • Dysregulated miRNAs are key drivers in the pathogenesis of hematological malignancies.
  • Specific miRNAs, like miR-155, act as oncogenes, while others, like miR-15a/16-1, function as tumor suppressors.

Conclusions:

  • MicroRNAs are critical regulators in both normal hematopoiesis and the development of blood cancers.
  • Understanding miRNA dysregulation in lymphoma offers potential therapeutic targets.